Skip to main content Accessibility help
×
Home

P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd

  • M. Bauer (a1), M. Thase (a2), S. Liu (a3), W. Earley (a3) and H. Eriksson (a4)...

Abstract

Introduction:

Two 6-week, double-blind, placebo-controlled studies evaluated quetiapine XR (QTP-XR) adjunct to ongoing antidepressant therapy in patients with MDD and an inadequate response to prior antidepressant treatment (D1448C00006/D1448C00007).

Objective and aim:

A post hoc pooled analysis examined clinical and demographic characteristics as potential predictors of response to adjunct QTP-XR

Methods:

Pooled MITT population (n = 616 QTP-XR [both doses]; n = 303 placebo) data were analysed from the two adjunct QTP-XR (150 or 300 mg/day) studies.

Effects of psychiatric history and baseline demographic and disease characteristics on efficacy were evaluated in subgroups based on Week 6 MADRS total score reduction: ≥50% reduction (responders: n = 345 QTP-XR, n = 140 placebo) versus < 50% (non-responders: n = 271 QTP-XR, n = 163 placebo); ≥75% reduction (responders: n = 175 QTP-XR, n = 60 placebo) versus < 25% (non-responders: n = 125 QTP-XR, n = 89 placebo).

Impact of baseline CGI-S score and number of episodes (0, 1, 2–3, 4–10, ≥10) over previous year and lifetime on Week 6 MADRS total score change was evaluated. Effect of baseline MADRS individual item (1–10) scores on Week 6 change in CGI-I score was evaluated.

Results:

No major differences between responders and non-responders to QTP-XR were observed for patient characteristics. there was no predictive association between baseline CGI-S score, number of depressive episodes, and baseline MADRS item scores and efficacy outcomes for adjunct QTP-XR.

Conclusions:

This pooled analysis showed no major differences between responders and non-responders, and no suggestion of a predictive association between the parameters assessed and efficacy outcomes for adjunct QTP-XR. Further investigation including logistic regression may be required.

AstraZeneca funded.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd
      Available formats
      ×

Copyright

P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd

  • M. Bauer (a1), M. Thase (a2), S. Liu (a3), W. Earley (a3) and H. Eriksson (a4)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

P-471 - Evaluation of Potential Predictors of Response to Treatment With Adjunct Extended Release Quetiapine Fumarate (quetiapine Xr) in Patients With Mdd

  • M. Bauer (a1), M. Thase (a2), S. Liu (a3), W. Earley (a3) and H. Eriksson (a4)...
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *